Isabel Steinig1, Felix von Podewils2, Gabriel Möddel3, Sebastian Bauer1,4, Karl Martin Klein1,4, Esther Paule1, Philipp S Reif1, Laurent M Willems1, Johann Philipp Zöllner1, Rhina Kunz2, Uwe Runge2, Gerhard Kurlemann5, Susanne Schubert-Bast1,6, Felix Rosenow1,4, Adam Strzelczyk1,4. 1. Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, Goethe-University, Frankfurt am Main, Germany. 2. Epilepsy Center Greifswald and Department of Neurology, Ernst-Moritz-Arndt-University, Greifswald, Germany. 3. Department of Sleep Medicine and Neuromuscular Disorders, Epilepsy Center Münster-Osnabrück, Westfälische Wilhelms-University, Münster, Germany. 4. Epilepsy Center Hessen and Department of Neurology, Philipps-University, Marburg, Germany. 5. Department of Neuropediatrics, Westfälische Wilhelms-University, Münster, Germany. 6. Department of Neuropediatrics, Goethe-University, Frankfurt am Main, Germany.
Abstract
OBJECTIVE: To evaluate factors predicting efficacy, retention, and tolerability of add-on brivaracetam (BRV) in clinical practice. METHODS: A multicenter, retrospective cohort study recruiting all patients who started BRV between February and November 2016 with observation time between 3 and 12 months. RESULTS: Of a total of 262 patients (mean age 40, range 5-81 years, 129 male) treated with BRV, 227 (87%) were diagnosed to have focal, 19 (7%) idiopathic generalized and 8 (3%) symptomatic generalized epilepsy, whereas 8 (3%) were unclassified. The length of exposure to BRV ranged from 1 day to 12 months, with a median retention time of 6.1 months, resulting in a total exposure time to BRV of 1,504 months. The retention rate was 79.4% at 3 months and 75.8% at 6 months. Efficacy at 3 months was 41.2% (50% responder rate) with 14.9% seizure-free for 3 months and, at 6 months, 40.5% with 15.3% seizure-free. Treatment-emergent adverse events were observed in 37.8% of the patients, with the most common being somnolence, dizziness, and behavioral adverse events (BAEs). BAE that presented under previous levetiracetam (LEV) treatment improved upon switch to BRV in 57.1% (20/35) and LEV-induced somnolence improved in 70.8% (17/24). Patients with BAE on LEV were more likely to develop BAE on BRV (odds ratio [OR] 3.48, 95% confidence interval [CI] 1.53-7.95). SIGNIFICANCE: BRV in broad clinical postmarketing use is a well-tolerated anticonvulsant drug with 50% responder rates, similar to those observed in the regulatory trials, even though 90% of the patients included had previously been exposed to LEV. An immediate switch from LEV to BRV at a ratio of 10:1 to 15:1 is feasible. The only independent significant predictor of efficacy was the start of BRV in patients not currently taking LEV. The occurrence of BAE during previous LEV exposure predicted poor psychobehavioral tolerability of BRV treatment. A switch to BRV can be considered in patients with LEV-induced BAE. Wiley Periodicals, Inc.
OBJECTIVE: To evaluate factors predicting efficacy, retention, and tolerability of add-on brivaracetam (BRV) in clinical practice. METHODS: A multicenter, retrospective cohort study recruiting all patients who started BRV between February and November 2016 with observation time between 3 and 12 months. RESULTS: Of a total of 262 patients (mean age 40, range 5-81 years, 129 male) treated with BRV, 227 (87%) were diagnosed to have focal, 19 (7%) idiopathic generalized and 8 (3%) symptomatic generalized epilepsy, whereas 8 (3%) were unclassified. The length of exposure to BRV ranged from 1 day to 12 months, with a median retention time of 6.1 months, resulting in a total exposure time to BRV of 1,504 months. The retention rate was 79.4% at 3 months and 75.8% at 6 months. Efficacy at 3 months was 41.2% (50% responder rate) with 14.9% seizure-free for 3 months and, at 6 months, 40.5% with 15.3% seizure-free. Treatment-emergent adverse events were observed in 37.8% of the patients, with the most common being somnolence, dizziness, and behavioral adverse events (BAEs). BAE that presented under previous levetiracetam (LEV) treatment improved upon switch to BRV in 57.1% (20/35) and LEV-induced somnolence improved in 70.8% (17/24). Patients with BAE on LEV were more likely to develop BAE on BRV (odds ratio [OR] 3.48, 95% confidence interval [CI] 1.53-7.95). SIGNIFICANCE: BRV in broad clinical postmarketing use is a well-tolerated anticonvulsant drug with 50% responder rates, similar to those observed in the regulatory trials, even though 90% of the patients included had previously been exposed to LEV. An immediate switch from LEV to BRV at a ratio of 10:1 to 15:1 is feasible. The only independent significant predictor of efficacy was the start of BRV in patients not currently taking LEV. The occurrence of BAE during previous LEV exposure predicted poor psychobehavioral tolerability of BRV treatment. A switch to BRV can be considered in patients with LEV-induced BAE. Wiley Periodicals, Inc.
Authors: Felix Zahnert; Kristina Krause; Ilka Immisch; Lena Habermehl; Iris Gorny; Izabella Chmielewska; Leona Möller; Anna M Weyand; Peter M Mross; Jan Wagner; Katja Menzler; Susanne Knake Journal: Front Neurol Date: 2018-02-06 Impact factor: 4.003
Authors: Katja Menzler; Peter Michael Mross; Felix Rosenow; Susanne Schubert-Bast; Laurent Maximilian Willems; Felix Zahnert; Ilka Immisch; Sven Fuest; Felix von Podewils; Rhina Kunz; Martin Hirsch; Tamara Mueller; Justus Marquetand; Yaroslav Winter; Lisa Langenbruch; Michal Cicanic; Stefan Beyenburg; Adam Strzelczyk; Susanne Knake Journal: BMJ Open Date: 2019-11-04 Impact factor: 2.692
Authors: Laurent M Willems; Astrid Bertsche; Frank Bösebeck; Frauke Hornemann; Ilka Immisch; Karl M Klein; Susanne Knake; Rhina Kunz; Gerhard Kurlemann; Lisa Langenbruch; Gabriel Möddel; Karen Müller-Schlüter; Felix von Podewils; Philipp S Reif; Bernhard J Steinhoff; Isabel Steinig; Felix Rosenow; Susanne Schubert-Bast; Adam Strzelczyk Journal: Front Neurol Date: 2018-07-23 Impact factor: 4.003
Authors: Jana E Jones; Miya R Asato; Mesha-Gay Brown; Julia L Doss; Elizabeth A Felton; Jennifer A Kearney; Delia Talos; Penny A Dacks; Vicky Whittemore; Annapurna Poduri Journal: Epilepsy Curr Date: 2020-01-23 Impact factor: 7.500